Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Assessment of the Rheumatoid Arthritis Market 2026-2036 Featuring Rise Therapeutics, Taiho Pharmaceutical, Abbvie, Eli Lilly/Incyte, and AstraZeneca

globenewswire.com
ABBV AbbVie's drug RINVOQ is mentioned as an approved rheumatoid arthritis therapy. The company is also listed as a key player in the competitive landscape. LLY Eli Lilly and Company's drug OLUMIANT is mentioned as an approved rheumatoid arthritis therapy. The company also has pipeline candidates like ocadusertib. It is listed as a key player. INCY Incyte is mentioned as a collaborator with Eli Lilly on the approved rheumatoid arthritis therapy OLUMIANT and is listed as a key player in the market. AZN AstraZeneca has pipeline candidates AZD1163 and AZD6912 for rheumatoid arthritis, with Phase II and Phase I development respectively. The company is listed as a key player. REGN Regeneron's drug KEVZARA (in partnership with Sanofi) is mentioned as an approved rheumatoid arthritis therapy. The company is listed as a key player. SNY Sanofi's drug KEVZARA (in partnership with Regeneron) is mentioned as an approved rheumatoid arthritis therapy. The company is listed as a key player. PFE Pfizer's drug XELJANZ is mentioned as an approved rheumatoid arthritis therapy. The company is listed as a key player.

Assessment of the Rheumatoid Arthritis Market 2026-2036 Featuring Rise Therapeutics, Taiho Pharmaceutical, Abbvie, Eli Lilly/Incyte, and AstraZeneca Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

Rheumatoid Arthritis Market Forecast to Reach New Growth Milestones Through 2036, Driven by Targeted Therapies and Expanding Patient Demand

The report provides a comprehensive analysis of the rheumatoid arthritis market across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The report examines historical and forecast epidemiology, treatment practices, marketed products, emerging therapies, competitive dynamics, market access, reimbursement, and commercial opportunities from 2022 through 2036.

Rheumatoid Arthritis Market Size and Forecast

The rheumatoid arthritis therapeutics market is expected to expand as prevalence increases, diagnostic capabilities improve, and treatment strategies continue to shift toward early intervention, sustained remission, and prevention of structural joint damage. Aging populations, long-term healthcare utilization, and the introduction of targeted biologic and oral therapies are also supporting market growth.

Nearly one in four Americans, or approximately 60 million people, is affected by arthritis. Rheumatoid arthritis accounts for a substantial share of chronic inflammatory disease burden, with persistent pain, functional impairment, disability, and extra-articular complications contributing to significant clinical and socioeconomic costs. Approximately 1.3 million adults in the United States are estimated to have rheumatoid arthritis, representing about 0.6%-1% of the adult population.

Epidemiological evidence also highlights important demographic differences. In the United Kingdom, adult prevalence has been estimated at approximately 0.81%, with a higher prevalence among women than men. Globally, women account for about 70% of people living with rheumatoid arthritis, while approximately 55% of patients are older than 55 years. Although rheumatoid arthritis mortality has declined over the past three decades, age-standardized prevalence and total diagnosed cases have increased.

Rheumatoid Arthritis Treatment Landscape

Current rheumatoid arthritis treatment aims to suppress inflammation, achieve remission or low disease activity, reduce symptoms, preserve physical function, and prevent irreversible joint and organ damage. Early initiation of disease-modifying antirheumatic drugs remains central to clinical management, supported by treat-to-target protocols and validated disease activity measures such as CDAI, DAS28, and SDAI.

Methotrexate remains a widely used first-line conventional DMARD based on its efficacy, tolerability, clinical familiarity, and cost profile. Patients with inadequate response may receive biologic DMARDs targeting TNF-?, interleukin pathways, T-cell co-stimulation, or B-cell activity. Targeted synthetic DMARDs, including Janus kinase inhibitors, have expanded the availability of oral treatment options for patients who do not respond adequately to conventional or biologic therapy.

Approved rheumatoid arthritis therapies include RINVOQ (upadacitinib) from AbbVie, OLUMIANT (baricitinib) from Eli Lilly and Company and Incyte, KEVZARA (sarilumab) from Regeneron and Sanofi, and XELJANZ (tofacitinib) from Pfizer. Other established products include TNF inhibitors such as HUMIRA, CIMZIA, and SIMPONI, as well as ACTEMRA and additional immunomodulatory therapies.

Upadacitinib received rheumatoid arthritis approvals in the United States and European Union in 2019, followed by Japan in 2020. Baricitinib received approval in the European Union and Japan in 2017 and in the United States in 2018 for eligible adults with moderately to severely active rheumatoid arthritis.

Rheumatoid Arthritis Pipeline and Emerging Therapies

The clinical pipeline includes candidates with differentiated mechanisms, routes of administration, and target populations. Programs highlighted in the report include AZD1163 and AZD6912 from AstraZeneca, ocadusertib from Eli Lilly and Company, R-2487 from Rise Therapeutics, MYMD-1 from TNF Pharmaceuticals, and TAS5315 from Taiho Pharmaceutical.

TAS5315 is being evaluated in a Phase II study in Japan in combination with methotrexate for patients who have experienced an inadequate response to methotrexate. The program targets BTK-mediated activity associated with B cells, macrophages, osteoclasts, inflammation, and bone erosion.

R-2487 is an oral immunotherapy under clinical investigation for rheumatoid arthritis and other autoimmune diseases. In January 2025, Rise Therapeutics announced completion of dose-escalation enrollment for the R-2487 and R-3750 clinical studies, allowing both programs to proceed to planned dose-expansion stages.

According to AstraZeneca's fiscal year 2025 clinical trial appendix, AZD1163 advanced to Phase II, while AZD6912 remained in Phase I. Data from both programs are anticipated after 2026. Pipeline development and future product launches could increase treatment choice while intensifying competition among established biologics, JAK inhibitors, and emerging therapeutic classes.

Market Drivers and Commercial Opportunities

Despite therapeutic progress, substantial unmet needs remain. These include inadequate or diminishing treatment response, limited predictive biomarkers, safety and tolerability concerns, delayed diagnosis, disease heterogeneity, therapy-switching challenges, and unequal access to advanced treatments. Addressing these gaps will be critical to improving long-term outcomes and supporting adoption of emerging rheumatoid arthritis therapies.

Market Access, Reimbursement, and Pricing Trends

The report evaluates country-level access, reimbursement, cost-effectiveness, affordability programs, public prescription coverage, and patient out-of-pocket costs. Reimbursement decisions remain closely associated with clinical benefit, comparative value, and therapy price. As high-cost biologics and targeted agents compete for preferred positioning, payers are considering alternative payment models and tighter evidence requirements.

Pricing and analogue assessment covers approved therapies and comparable products for pipeline candidates. This analysis examines how price positioning may influence formulary access, physician prescribing, patient adherence, market penetration, and long-term uptake across the United States, Europe, and Japan.

Competitive Intelligence and Expert Validation

Key companies covered include AbbVie, Eli Lilly and Company, Incyte, AstraZeneca, Rise Therapeutics, Taiho Pharmaceutical, Regeneron, Sanofi, Pfizer, and other established and emerging rheumatoid arthritis market participants. Drug profiles assess clinical data, mechanisms of action, regulatory status, patent considerations, collaborations, strategic partnerships, development catalysts, advantages, and limitations.

The analysis incorporates insights from more than 15 key opinion leaders and subject-matter experts across major markets. Expert engagement supports evaluation of prescribing patterns, therapy switching, patient adherence, access barriers, emerging drug adoption, epidemiology, and evolving standards of care. SWOT and conjoint analyses further compare therapies according to efficacy, safety, administration frequency, route of administration, market-entry timing, probability of success, and addressable patient population.

Report Highlights

The report is designed to support pharmaceutical companies, investors, healthcare organizations, and other industry stakeholders in assessing the rheumatoid arthritis market opportunity. Its integrated analysis of epidemiology, clinical development, competitive positioning, pricing, and physician perspectives provides actionable intelligence for portfolio planning, product development, market access, and launch strategy through 2036.

For more information about this report visit https://www.researchandmarkets.com/r/yce4lm

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.